Health Care · Services-Medical Laboratories · Nasdaq · CIK 1674930 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $19.64Day +0.05%Mkt cap $558M1Y +11.8%Off 52W high −36.7%Vol (1Y) 57.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,467 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest9.7% of sh out |
| Days to cover11.4d |
| 13F net flow (QoQ)−1.51% |
| Top-10 13F concentration55.1% |
| Next report (est.)2026-07-31 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$320.3M |
| Earnings (TTM)-$73.8M |
| ROE−5.4% |
| Net margin−18.8% |
| ROIC−6.8% |
| Sales growth 3Y−19.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−25.2% |
| 1Y+11.8% |
| 3Y−49.4% |
| 5Y−78.6% |
| Since incept. (ann.)+8.0% |
Total return through 2026-07-29 · series begins 2016-09-29. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)57.6% |
| Ann. volatility (3Y)47.8% |
| Sharpe (1Y)0.48 |
| Sharpe (3Y)−0.22 |
| Max drawdown (1Y)−55.3% |
| Max drawdown (3Y)−65.6% |
| Beta (3Y vs SPY)0.65 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 2.8M | $44M | 9.77% | −6.3% |
| RTW INVESTMENTS, LP | 1.3M | $20M | 4.54% | +82.8% |
| ACADIAN ASSET MANAGEMENT LLC | 1.2M | $20M | 4.34% | +4.1% |
| VANGUARD CAPITAL MANAGEMENT LLC | 880,150 | $14M | 3.10% | new |
| DIMENSIONAL FUND ADVISORS LP | 671,664 | $11M | 2.36% | −24.4% |
| Invenomic Capital Management LP | 610,318 | $10M | 2.15% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 584,207 | $9M | 2.06% | +15.0% |
| AMERIPRISE FINANCIAL INC | 563,375 | $9M | 1.98% | +12.8% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-01 | — | — | $71.1M | −3.2% |
| 2025-12-31 | 2026-02-27 | — | — | $83.3M | +9.3% |
| 2025-09-30 | 2025-11-07 | — | — | $84.1M | +17.2% |
| 2025-06-30 | 2025-08-01 | — | — | $81.8M | +15.2% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-07-31 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Laboratory Services 100% · Therapeutic Development 0%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
